iOmx Therapeutics is focused on developing next-generation targeted cancer immunotherapies by leveraging insights from tumor and myeloid biology. The company utilizes its proprietary iOTarg™ target screening platform to identify novel immune evasion strategies directly from tumor samples. This systematic approach enables iOmx to generate a pipeline of biomarker-enabled drug candidates aimed at addressing prevalent solid tumor indications. Their lead candidate, OMX-0407, is a first-in-class SIK inhibitor that enhances apoptosis in tumor cells by downregulating pathways that allow tumors to evade immune responses. This candidate is currently undergoing a first-in-human clinical trial, showcasing iOmx's commitment to advancing innovative cancer treatments.

In addition to OMX-0407, iOmx is developing IOMX-0675, a dual-targeting monoclonal antibody that targets the immunosuppressive receptors LILRB1 and LILRB2 on myeloid and lymphoid immune cells. By selectively neutralizing these receptors, IOMX-0675 aims to reactivate both innate and adaptive immune responses, thereby enhancing anti-tumor activity. This antibody is currently in IND-enabling studies, with plans for clinical entry in early 2025. Through these innovative approaches, iOmx Therapeutics is dedicated to shaping the future of cancer therapy by creating effective treatments that can potentially serve as backbone therapies in oncology.

Germany

iOmx is a young, dynamic start-up in the field of immuno-oncology located in Martinsried/Munich, Germany. Backed by a powerful technology platform and internationally renowned investors, iOmx is driving forward a cutting-edge portfolio of early-stage novel immune-checkpoint drugs through pre-clinical and clinical development.

IOmx Therapeutics

Company Details